ロード中...
Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
Program death receptor-1 (PD-1) and program death receptor-1 ligand (PD-L1) inhibitors are increasingly being used in the clinic to treat a growing number of malignancies, including many genitourinary (GU) malignancies. These immune-based therapies have demonstrated a distinct toxicity profile compa...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5377000/ https://ncbi.nlm.nih.gov/pubmed/28421161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00056 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|